{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/peripheral-arterial-disease/background-information/complications/","result":{"pageContext":{"chapter":{"id":"cdbbc165-3643-5f50-8f32-9fc5504ba2ef","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field b911c388-f4c8-42b5-ba3a-de2a61043e26 --><h2>What are the complications?</h2><!-- end field b911c388-f4c8-42b5-ba3a-de2a61043e26 -->","summary":"","htmlStringContent":"<!-- begin item 98e25ff8-7b42-4239-85f1-3d6e584bb2d5 --><!-- begin field 49a0243f-aba4-49cf-a086-deb2336f54d8 --><ul><li><strong>Complications of peripheral arterial disease include:</strong><ul><li><strong>Impairment of quality of life </strong>by claudication and limitation of mobility [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2015</a>].</li><li><strong>Psychosocial consequences</strong> such as depression — associated with advanced peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Shishehbor et al, 2016</a>]. </li><li><strong>Tissue loss (ulceration and gangrene) </strong>in chronic limb-threatening ischaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>]. Risk of amputation is increased in people with critical limb ischaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>]. Not many people with intermittent claudication develop complications that are limb-threatening (1–3% over 5 years) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>]. </li><li><strong>Procedural complications </strong>in people undergoing invasive treatments for peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2015</a>]. </li></ul></li><li><strong>People with peripheral arterial disease are also at high risk of vascular complications</strong> such as myocardial infarction, stroke, vascular dementia, renovascular disease, and mesenteric disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Cea-Soriano et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>]. Atherosclerosis is often generalised and, if it is present at one site, there is an overall risk of cardiovascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>]. </li><li><strong>Complications of acute limb ischaemia include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Santistevan, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">McNally and Univers, 2018</a>]: <ul><li>Compartment syndrome — reperfusion of ischaemic muscles can cause oedema and increased compartmental pressure.</li><li>Reperfusion injury — products of cell death (for example potassium, phosphate and myoglobin) are released when blood flow to the ischaemic limb is restored. This can result in rhabdomyolysis, cardiac dysrhythmia, acute kidney injury, multiorgan failure, and disseminated intravascular coagulation. </li></ul></li></ul><!-- end field 49a0243f-aba4-49cf-a086-deb2336f54d8 --><!-- end item 98e25ff8-7b42-4239-85f1-3d6e584bb2d5 -->","topic":{"id":"fff7e03a-2313-5ab5-b744-9c6bba67aa6b","topicId":"deeaf796-d620-42bf-903e-a43ff99b1d1d","topicName":"Peripheral arterial disease","slug":"peripheral-arterial-disease","lastRevised":"Last revised in September 2019","chapters":[{"id":"9e988871-ea98-52a6-bb9d-910e22b3a6dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81e6bfaf-7c78-52e2-b11d-8e2315ebe9e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fee65eb3-86d0-571b-9815-f9407ec29fa7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"239ddbef-73a4-5941-9dc8-52d73689e140","slug":"changes","fullItemName":"Changes"},{"id":"39825e21-a7b7-573c-86a7-fd5d87a847d3","slug":"update","fullItemName":"Update"}]},{"id":"da348d6d-4102-5de5-b9be-d28e7c83e8d0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f3f64c-323d-5c10-b5ff-9df793eab0d8","slug":"goals","fullItemName":"Goals"},{"id":"504b7741-50ac-5c4c-ac51-ea56d8cc4c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a7e09ccb-6701-5658-a01c-52a02d7f9f80","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a54b63f6-0b42-5584-91e8-027e613f7246","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f6168c43-2e36-5e1d-bb44-04674d098b73","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"67399dd0-adb5-5b36-a616-cfc0605ebe52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9c30093e-b7fa-5c0f-84d0-465bf0768823","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8f766fdc-ff98-5227-9d99-fe65802aaaca","slug":"definition","fullItemName":"Definition"},{"id":"4c33be40-568c-527a-8936-a79726b11e66","slug":"causes","fullItemName":"Causes"},{"id":"b8817533-a2e9-531b-9c51-d1c3da17b2ef","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ea6fdfd8-a5f7-52de-ac19-8a05fd53556f","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cdbbc165-3643-5f50-8f32-9fc5504ba2ef","slug":"complications","fullItemName":"Complications"},{"id":"59787aa9-8de0-5efd-b54e-2d72c75845a5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"59e978dc-e4bc-574d-a047-413f87ec6b3d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ea4a531c-cf38-5e54-85d9-1f845bf7582f","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"ebe23574-b6e5-5812-816c-6955392cee34","slug":"assessment","fullItemName":"Assessment"},{"id":"c501646c-c9a8-5372-ae9c-c0aab453c6e5","slug":"features-of-acute-limb-ischaemia","fullItemName":"Features of acute limb ischaemia"},{"id":"fdc33cb6-26a1-58c3-8eab-79d69745d871","slug":"features-of-intermittent-claudication-critical-limb-ischaemia","fullItemName":"Features of intermittent claudication and critical limb ischaemia"},{"id":"8c98aa45-6aef-5b47-a997-e9eeec827356","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04fcdfca-c3cb-56b4-a18e-535c5a54e1a9","fullItemName":"Management","slug":"management","subChapters":[{"id":"fb3fcf0a-56a8-5693-b5ef-75e12c6f1f11","slug":"acute-limb-ischaemia","fullItemName":"Scenario: Acute limb ischaemia"},{"id":"d89d9e21-f892-533e-a3b8-e5649a205398","slug":"critical-limb-ischaemia","fullItemName":"Scenario: Critical limb ischaemia"},{"id":"357ee79f-9fa4-57e7-abd7-7881201f1629","slug":"intermittent-claudication","fullItemName":"Scenario: Intermittent claudication"}]},{"id":"da28584d-59b4-5a06-9357-9484a9bf93cc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e3ab00c1-43b9-58c7-a1c4-44198627e4ab","slug":"naftidrofuryl-oxalate","fullItemName":"Naftidrofuryl oxalate"},{"id":"bb79b6c3-de22-58b3-9244-5ae82a6133ad","slug":"paracetamol-weak-opioids","fullItemName":"Paracetamol and weak opioids"}]},{"id":"1545d985-832b-5a4a-abc9-bd7f0c21b754","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"049d6682-f78d-5c05-bdfb-1dbd5e91b017","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"58d7e6c5-f97f-507d-b627-87ab85bde479","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"574b8e96-33b9-5191-81dd-f415c704abf9","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3df8039-73c2-5c30-b7e8-2566977e32dc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d466274b-a2ab-58f1-badc-abfed7066e4f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaed3513-3a59-5991-8410-2c4446539abd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74346084-c291-5a06-ac3d-a0ae85243940","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9c30093e-b7fa-5c0f-84d0-465bf0768823","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}